Compare $APUS vs $BOLT | Chartloom

Compare

$APUS vs $BOLT

Apimeds Pharmaceuticals US Inc · Bolt Biotherapeutics Inc

APUS

Apimeds Pharmaceuticals US Inc

BOLT

Bolt Biotherapeutics Inc

Compare $APUS vs $BOLT

Comparing Apimeds Pharmaceuticals US Inc and Bolt Biotherapeutics Inc

APUSApimeds Pharmaceuticals US Inc

BOLTBolt Biotherapeutics Inc

APUSApimeds Pharmaceuticals US Inc

Market cap

$8M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-69.8%

52W performance

-75.9%

FCF yield

-70.6%

BOLTBolt Biotherapeutics Inc

Market cap

$8M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

12.8%

YTD performance

-29.0%

52W performance

-35.8%

FCF yield

-399.6%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

APUS

BOLT

Detailed metrics comparison

APUS

Apimeds Pharmaceuticals US Inc

BOLT

Bolt Biotherapeutics Inc

Market Cap

APUS$8M

BOLT$8M

Enterprise Value

APUS$22M

BOLT$-5M

Price

APUS$5.02

BOLT$4.11

P/E Ratio

APUSN/A

BOLTN/A

P/S Ratio

APUS0.00x

BOLT1.68x

EV/Sales

APUS0.00x

BOLT-1.06x

EV/EBITDA

APUS0.00x

BOLT0.00x

P/B Ratio

APUS0.05x

BOLT0.53x

P/FCF Ratio

APUSN/A

BOLTN/A

EV/FCF

APUS-4.06x

BOLT0.16x

PEG Ratio

APUSN/A

BOLTN/A

Forward P/E (NTM)

APUSN/A

BOLTN/A

Forward P/S (NTM)

APUSN/A

BOLTN/A

Revenue (TTM)

APUS$0

BOLT$5M

Revenue Growth (YoY)

APUSN/A

BOLT12.8%

Forward Rev Growth

APUS0.0%

BOLT1650.0%

Gross Margin (TTM)

APUS0.0%

BOLT0.0%

Operating Margin (TTM)

APUS0.0%

BOLT0.0%

EBITDA Margin (TTM)

APUS0.0%

BOLT-586.3%

Net Margin (TTM)

APUS0.0%

BOLT-611.5%

FCF Margin (TTM)

APUSN/A

BOLT-671.0%

Net Income (TTM)

APUS$-58M

BOLT$-29M

FCF (TTM)

APUS$-5M

BOLT$-32M

EPS (TTM)

APUS-$33.95

BOLT-$17.00

ROE (TTM)

APUS-5898.0%

BOLT-12623.0%

ROA (TTM)

APUS-5261.0%

BOLT-5470.0%

ROIC (TTM)

APUS-5458.0%

BOLT-12623.0%

Cash

APUS$278K

BOLT$13M

Debt

APUS$14M

BOLT$0

Net Cash/Debt

APUS$-14M

BOLT$13M

Current Ratio (TTM)

APUS0.51x

BOLT2.61x

Quick Ratio (TTM)

APUS0.40x

BOLT2.26x

Debt/Equity (TTM)

APUS0.14x

BOLT0.00x

Debt/Assets (TTM)

APUS0.0%

BOLT0.0%

Interest Coverage (TTM)

APUSN/A

BOLTN/A

Net Debt/EBITDA (TTM)

APUS0.00x

BOLT0.00x

Beta

APUS2.60

BOLT0.97

52W Performance

APUS-75.9%

BOLT-35.8%

YTD Performance

APUS-69.8%

BOLT-29.0%

% from 52W High

APUS-91.6%

BOLT-42.9%

% from 52W Low

APUS232.5%

BOLT32.6%

Asset Turnover (TTM)

APUS0.00x

BOLT0.09x

FCF Yield (TTM)

APUS-70.6%

BOLT-399.6%

Earnings Yield (TTM)

APUS-767.4%

BOLT-364.2%

Dividend Yield (TTM)

APUSN/A

BOLTN/A

Rule of 40

APUS0.0

BOLT-658.2

EV/GP/RG

APUSN/A

BOLTN/A

Ticker research

View APUS research View BOLT research

Metric	APUS Apimeds Pharmaceuticals US Inc	BOLT Bolt Biotherapeutics Inc
Market & Valuation
Market Cap	$8M	$8M
Enterprise Value	$22M	$-5M
Price	$5.02	$4.11
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	1.68x
EV/Sales	0.00x	-1.06x
EV/EBITDA	0.00x	0.00x
P/B Ratio	0.05x	0.53x
P/FCF Ratio	N/A	N/A
EV/FCF	-4.06x	0.16x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$0	$5M
Revenue Growth (YoY)	N/A	12.8%
Forward Rev Growth	0.0%	1650.0%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-586.3%
Net Margin (TTM)	0.0%	-611.5%
FCF Margin (TTM)	N/A	-671.0%
Net Income (TTM)	$-58M	$-29M
FCF (TTM)	$-5M	$-32M
EPS (TTM)	-$33.95	-$17.00
ROE (TTM)	-5898.0%	-12623.0%
ROA (TTM)	-5261.0%	-5470.0%
ROIC (TTM)	-5458.0%	-12623.0%
Financial Health
Cash	$278K	$13M
Debt	$14M	$0
Net Cash/Debt	$-14M	$13M
Current Ratio (TTM)	0.51x	2.61x
Quick Ratio (TTM)	0.40x	2.26x
Debt/Equity (TTM)	0.14x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	2.60	0.97
52W Performance	-75.9%	-35.8%
YTD Performance	-69.8%	-29.0%
% from 52W High	-91.6%	-42.9%
% from 52W Low	232.5%	32.6%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.09x
FCF Yield (TTM)	-70.6%	-399.6%
Earnings Yield (TTM)	-767.4%	-364.2%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	-658.2
EV/GP/RG	N/A	N/A
Ticker research	View APUS research	View BOLT research

Valuation

P/S Ratio

APUS

0.00x

BOLT

1.68x

EV/FCF

APUS

-4.06x

BOLT

0.16x

Growth & revenue

Revenue Growth TTM

BOLT

12.8%

Forward Revenue Growth

BOLT

1650.0%

APUS

0.0%

Profitability & performance

Gross Margin

APUS

0.0%

BOLT

0.0%

ROE

APUS

-5898.0%

BOLT

-12623.0%

FCF Yield %

APUS

-70.6%

BOLT

-399.6%

52-Week Performance

BOLT

-35.8%

APUS

-75.9%

Detailed metrics comparison

APUS

Apimeds Pharmaceuticals US Inc

BOLT

Bolt Biotherapeutics Inc

Market Cap

APUS$8M

BOLT$8M

Enterprise Value

APUS$22M

BOLT$-5M

Price

APUS$5.02

BOLT$4.11

P/E Ratio

APUSN/A

BOLTN/A

P/S Ratio

APUS0.00x

BOLT1.68x

EV/Sales

APUS0.00x

BOLT-1.06x

EV/EBITDA

APUS0.00x

BOLT0.00x

P/B Ratio

APUS0.05x

BOLT0.53x

P/FCF Ratio

APUSN/A

BOLTN/A

EV/FCF

APUS-4.06x

BOLT0.16x

PEG Ratio

APUSN/A

BOLTN/A

Forward P/E (NTM)

APUSN/A

BOLTN/A

Forward P/S (NTM)

APUSN/A

BOLTN/A

Revenue (TTM)

APUS$0

BOLT$5M

Revenue Growth (YoY)

APUSN/A

BOLT12.8%

Forward Rev Growth

APUS0.0%

BOLT1650.0%

Gross Margin (TTM)

APUS0.0%

BOLT0.0%

Operating Margin (TTM)

APUS0.0%

BOLT0.0%

EBITDA Margin (TTM)

APUS0.0%

BOLT-586.3%

Net Margin (TTM)

APUS0.0%

BOLT-611.5%

FCF Margin (TTM)

APUSN/A

BOLT-671.0%

Net Income (TTM)

APUS$-58M

BOLT$-29M

FCF (TTM)

APUS$-5M

BOLT$-32M

EPS (TTM)

APUS-$33.95

BOLT-$17.00

ROE (TTM)

APUS-5898.0%

BOLT-12623.0%

ROA (TTM)

APUS-5261.0%

BOLT-5470.0%

ROIC (TTM)

APUS-5458.0%

BOLT-12623.0%

Cash

APUS$278K

BOLT$13M

Debt

APUS$14M

BOLT$0

Net Cash/Debt

APUS$-14M

BOLT$13M

Current Ratio (TTM)

APUS0.51x

BOLT2.61x

Quick Ratio (TTM)

APUS0.40x

BOLT2.26x

Debt/Equity (TTM)

APUS0.14x

BOLT0.00x

Debt/Assets (TTM)

APUS0.0%

BOLT0.0%

Interest Coverage (TTM)

APUSN/A

BOLTN/A

Net Debt/EBITDA (TTM)

APUS0.00x

BOLT0.00x

Beta

APUS2.60

BOLT0.97

52W Performance

APUS-75.9%

BOLT-35.8%

YTD Performance

APUS-69.8%

BOLT-29.0%

% from 52W High

APUS-91.6%

BOLT-42.9%

% from 52W Low

APUS232.5%

BOLT32.6%

Asset Turnover (TTM)

APUS0.00x

BOLT0.09x

FCF Yield (TTM)

APUS-70.6%

BOLT-399.6%

Earnings Yield (TTM)

APUS-767.4%

BOLT-364.2%

Dividend Yield (TTM)

APUSN/A

BOLTN/A

Rule of 40

APUS0.0

BOLT-658.2

EV/GP/RG

APUSN/A

BOLTN/A

Ticker research

View APUS research View BOLT research

Metric	APUS Apimeds Pharmaceuticals US Inc	BOLT Bolt Biotherapeutics Inc
Market & Valuation
Market Cap	$8M	$8M
Enterprise Value	$22M	$-5M
Price	$5.02	$4.11
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	1.68x
EV/Sales	0.00x	-1.06x
EV/EBITDA	0.00x	0.00x
P/B Ratio	0.05x	0.53x
P/FCF Ratio	N/A	N/A
EV/FCF	-4.06x	0.16x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$0	$5M
Revenue Growth (YoY)	N/A	12.8%
Forward Rev Growth	0.0%	1650.0%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-586.3%
Net Margin (TTM)	0.0%	-611.5%
FCF Margin (TTM)	N/A	-671.0%
Net Income (TTM)	$-58M	$-29M
FCF (TTM)	$-5M	$-32M
EPS (TTM)	-$33.95	-$17.00
ROE (TTM)	-5898.0%	-12623.0%
ROA (TTM)	-5261.0%	-5470.0%
ROIC (TTM)	-5458.0%	-12623.0%
Financial Health
Cash	$278K	$13M
Debt	$14M	$0
Net Cash/Debt	$-14M	$13M
Current Ratio (TTM)	0.51x	2.61x
Quick Ratio (TTM)	0.40x	2.26x
Debt/Equity (TTM)	0.14x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	2.60	0.97
52W Performance	-75.9%	-35.8%
YTD Performance	-69.8%	-29.0%
% from 52W High	-91.6%	-42.9%
% from 52W Low	232.5%	32.6%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.09x
FCF Yield (TTM)	-70.6%	-399.6%
Earnings Yield (TTM)	-767.4%	-364.2%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	-658.2
EV/GP/RG	N/A	N/A
Ticker research	View APUS research	View BOLT research